21
SEP
2016

NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London

Posted By :
Comments : Off
Dr. Marnix Bosch, Chief Technical Officer, Presented   BETHESDA, MD, September 21, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines...
Read More
06
SEP
2016

NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

Posted By :
Comments : Off
Shares and Warrants To Be Cancelled and Reduced; MFN To Be Removed from Contracts BETHESDA, Md., September 6, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Nasdaq has accepted NW Bio’s proposed remediation plan to resolve Nasdaq’s finding, previously disclosed by the Company, that NW Bio...
Read More
05
JUL
2016

NW Bio Announced a Registered Direct Offering of $3.7 Million With New Institutional Investors

Posted By :
Comments : Off
BETHESDA, Md., July 5, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with two new institutional investors for a registered direct offering with gross proceeds of $3.7 million. The Company will sell to the investors approximately 7.4 million shares of common stock at...
Read More
30
JUN
2016

NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement

Posted By :
Comments : Off
Progress Also Reported On Additional Nasdaq Compliance Issue   BETHESDA, MD, June 30, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced it had filed an 8-K today relating to two outstanding Nasdaq issues, including progress on a remediation plan relating to certain prior stock issuances. On June 24, 2016, Northwest...
Read More
13
JUN
2016

NW Bio Announces Scientific Advisory Board

Posted By :
Comments : Off
Leading Experts in Immunotherapies and Oncology From Both the US and Europe   BETHESDA, MD, June 13, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe. The Company anticipates that the SAB...
Read More